Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for the stock price over the next six months [4]. Core Insights - The company achieved a significant revenue increase of 231.6% year-on-year, reaching 663 million yuan in 2025, while narrowing its net loss to 969 million yuan, a reduction of 74.58 million yuan compared to the previous year [1][4]. - The company’s research and development investment rose by 24.8% to 977 million yuan, reflecting a commitment to innovation and pipeline development [1]. - The company reported a substantial improvement in operating cash flow, with a net cash flow of 290 million yuan in 2025 [2]. Revenue Breakdown - Licensing revenue accounted for over 60% of total revenue, with a remarkable growth of 642.4% year-on-year, totaling 409 million yuan, primarily from collaborations with Qilu Pharmaceutical and CALICO [2]. - Drug sales revenue reached 250 million yuan, a 72.7% increase, with the drug Deshu single antibody contributing 206 million yuan, representing over 80% of drug revenue [2]. Clinical and Regulatory Developments - The company has completed enrollment for three Phase III clinical trials for its Nectin-4 ADC (9MW2821), targeting urothelial carcinoma, cervical cancer, and triple-negative breast cancer, with mid-term analysis planned for the second half of 2026 [3]. - The anti-ST2 monoclonal antibody (9MW1911) showed a significant reduction of over 30% in annualized acute exacerbation rates in moderate to severe COPD patients compared to the placebo group [3]. - The company has made strides in international markets, with two formulations of Deshu single antibody receiving approval in Pakistan, marking the company's first overseas registration [3]. Financial Forecast and Valuation - Revenue projections for 2026 to 2028 are estimated at 1.14 billion yuan, 1.83 billion yuan, and 2.06 billion yuan, respectively, with net losses expected to decrease to 593 million yuan in 2026 and further to 211 million yuan by 2028 [4]. - The report anticipates a gross margin of 90.3% in 2025, improving to 91.0% by 2028 [11].

Core Viewpoint - BeiGene achieved a revenue of $5.34 billion in 2025, representing a year-on-year increase of 40%, with product revenue of $5.28 billion, slightly exceeding previous management guidance of $5-5.3 billion [1] Group 1: Financial Performance - The company reported a net profit of $290 million, recovering from a loss of $640 million in the previous year, marking a turnaround in recurring business [1] - Management expects revenue to reach $6.2-6.4 billion in 2026, with GAAP operating profit projected at $700-800 million [1] Group 2: Product Performance - Zanubrutinib generated $3.93 billion in revenue for the year, up 49% year-on-year, with U.S. sales of $2.8 billion (up 45%), European sales of $600 million (up 66%), and Chinese sales of $340 million (up 33%) [1] - In Q4 2025, Zanubrutinib revenue was $1.15 billion, reflecting a quarter-on-quarter increase of 10% and a year-on-year increase of 38% [1] - Tislelizumab achieved $740 million in revenue for the year, a 19% increase year-on-year, with Q4 2025 revenue of $180 million, down 5% quarter-on-quarter but up 18% year-on-year [1] - Revenue from cooperative products in China reached $620 million, a 20% increase year-on-year, driven by growth in Duzallo and Belantamab Mafodotin [1] Group 3: Future Catalysts - Key catalysts for 1H26 include the approval of Sotorasib for R/R MCL in the U.S. and interim analysis for Zanubrutinib in 1L MCL Phase III trials [2] - In 2H26, the company plans to submit an accelerated approval application for BTK CDAC based on Phase II clinical data for R/R CLL and initiate Phase III trials for Sotorasib in combination therapy for multiple myeloma [2] - The revenue forecasts for FY26 and FY27 are maintained at $6.4 billion and $7.1 billion, respectively, with slight adjustments to net profit estimates reflecting increased R&D expenditures [2] - The target price is set at HKD 212.09, maintaining an "outperform" rating based on a DCF model with a WACC of 9% and a perpetual growth rate of 4% [2]

Core Viewpoint - Haitong International maintains an "outperform" rating for BeiGene (06160), with revenue forecasts for FY26 and FY27 at $6.4 billion and $7.1 billion respectively, and slightly adjusts net profit forecasts to $610 million and $1.04 billion for the same periods [1] Group 1: Financial Performance - In 2025, BeiGene achieved revenue of $5.34 billion, a year-on-year increase of 40%, with product revenue of $5.28 billion, slightly exceeding previous management guidance [1] - The net profit attributable to shareholders for 2025 was $290 million, marking a turnaround in annual recurring business [1] - Management anticipates revenue of $6.2 billion to $6.4 billion for 2026, with GAAP operating profit projected at $700 million to $800 million [1] Group 2: Product Performance - Zepzelca generated revenue of $3.93 billion for the year, a 49% increase year-on-year, with U.S. sales at $2.8 billion (up 45%), European sales at $600 million (up 66%), and Chinese sales at $340 million (up 33%) [2] - The quarterly revenue for Zepzelca in Q4 2025 was $1.15 billion, reflecting a 10% increase quarter-on-quarter and a 38% increase year-on-year [2] - Tislelizumab achieved annual revenue of $740 million, a 19% increase year-on-year, with Q4 2025 revenue of $180 million, up 18% year-on-year [2] - Collaborative product sales in China totaled $620 million for the year, a 20% increase, driven by growth in Duzallo and Belantamab Mafodotin [2] Group 3: Upcoming Catalysts - Key catalysts for 1H26 include the approval of Sotigalimab for R/RMCL in the U.S., interim analysis of Zepzelca in 1L-MCL Phase III, initiation of CDK4 in 1L-HR+ HER2- BC Phase III, and data readout for BTKCDAC in moderate to severe chronic spontaneous urticaria Phase Ib [3] - In 2H26, key catalysts include submission of BTKCDAC for accelerated approval based on Phase II clinical data for R/R-CLL, initiation of Sotigalimab in a triplet regimen for 2L+ multiple myeloma Phase III, and expected initiation of BGB-B2033 (GPC3x41BB) for gastrointestinal cancer in a potential registrational Phase II study [3]

Group 1 - The core viewpoint of Haitong International maintains an "outperform" rating for BeiGene (06160), with revenue forecasts for FY26 and FY27 at $6.4 billion and $7.1 billion respectively, and a slight adjustment of net profit forecasts to $610 million and $1.04 billion [1] - The company achieved revenue of $5.34 billion in 2025, a year-on-year increase of 40%, with product revenue of $5.28 billion, slightly exceeding previous management guidance [1] - Management anticipates revenue of $6.2 billion to $6.4 billion in 2026, with GAAP operating profit projected at $700 million to $800 million [1] Group 2 - The revenue for Zebutini reached $3.93 billion in 2025, reflecting a 49% year-on-year growth, with U.S. sales at $2.8 billion (up 45%), European sales at $600 million (up 66%), and Chinese sales at $340 million (up 33%) [2] - The revenue for Tislelizumab was $740 million in 2025, showing a 19% year-on-year increase, with Q4 2025 revenue at $180 million (up 18%) [2] - Revenue from collaborative products in China was $620 million, a 20% increase, driven by growth in Duzallo and Belantamab Mafodotin [2] Group 3 - Key catalysts for 1H26 include the approval of Sotigalimab for R/RMCL in the U.S., interim analysis of Zebutini in the Phase III trial for 1L MCL, and the expected initiation of Phase III clinical trials for CDK4 in HR+ HER2- BC [3] - In 2H26, key catalysts include the submission of an accelerated approval application for BTKCDAC based on Phase II clinical data for R/R CLL, initiation of a Phase III trial for Sotigalimab in combination therapy for 2L+ multiple myeloma, and expected initiation of a potential registration Phase II study for BGB-B2033 in gastrointestinal cancer [3]

Investment Rating - The report maintains an "Outperform" rating for BeiGene [2][5][14]. Core Insights - In FY25, BeiGene achieved revenue of USD 5.34 billion, representing a 40% year-over-year increase, with product revenue of USD 5.28 billion, slightly exceeding management's guidance [3][11]. - The net profit attributable to the parent company was USD 0.29 billion, a turnaround from a loss of USD 0.64 billion in FY24, indicating a successful operational recovery [3][11]. - Management projects FY26 revenue to be between USD 6.2 billion and USD 6.4 billion, with GAAP operating profit expected to be between USD 0.7 billion and USD 0.8 billion [3][11]. Financial Summary - Revenue growth is forecasted at 55% for FY25, 40% for FY26, and 20% for FY27 [9]. - Net profit is expected to grow significantly, with projections of USD 0.61 billion for FY26 and USD 1.04 billion for FY27, reflecting a 113% and 70% increase, respectively [9][14]. - Gross profit margin is expected to remain strong at around 87.5% for FY26 and FY27 [9]. Sales Performance - Zanubrutinib generated full-year revenue of USD 3.93 billion, up 49% year-over-year, with U.S. sales contributing USD 2.8 billion [12]. - Tislelizumab achieved revenue of USD 0.74 billion, marking a 19% increase year-over-year [13]. - Collaboration product sales in China reached USD 0.62 billion, driven by growth in specific drugs [13]. Future Catalysts - Key catalysts for 1H26 include the approval of Sonrotoclax for R/R MCL and interim analysis of zanubrutinib in 1L MCL [16]. - In 2H26, significant events include the submission for accelerated approval of BTK CDAC and the initiation of a Phase 3 trial for Sonrotoclax in combination therapy for multiple myeloma [16]. Valuation - The target price is set at HKD 212.09, based on a discounted cash flow (DCF) model with a WACC of 9% and a perpetual growth rate of 4% [5][14].

Investment Rating - The report maintains an "Outperform" rating for BeiGene [2][14]. Core Insights - In FY25, BeiGene achieved revenue of USD 5.34 billion, representing a 40% year-over-year increase, with product revenue of USD 5.28 billion, slightly exceeding management's guidance [3][11]. - The net profit attributable to the parent company was USD 0.29 billion, a turnaround from a loss of USD 0.64 billion in FY24, indicating a successful operational recovery [3][11]. - Management projects FY26 revenue to be between USD 6.2 billion and USD 6.4 billion, with GAAP operating profit expected to be between USD 0.7 billion and USD 0.8 billion [3][11]. Financial Summary - Revenue growth is forecasted at 55% for FY25, 40% for FY26, and 20% for FY27 [9]. - Net profit is expected to grow significantly, with projections of USD 0.61 billion for FY26 and USD 1.04 billion for FY27, reflecting a 113% and 70% increase respectively [9][14]. - Gross profit margin is projected to remain strong at around 87.5% for FY26 and FY27 [9]. Sales Performance - Zanubrutinib generated full-year revenue of USD 3.93 billion, up 49% year-over-year, with significant contributions from the U.S. market [12]. - Tislelizumab achieved revenue of USD 0.74 billion, marking a 19% increase year-over-year [13]. - Collaboration product sales in China reached USD 0.62 billion, driven by growth in specific drugs [13]. Future Catalysts - Key catalysts for 1H26 include the approval of Sonrotoclax for R/R MCL and interim analysis of zanubrutinib in 1L MCL [16]. - In 2H26, significant events include the submission for accelerated approval of BTK CDAC and the initiation of a Phase 3 trial for Sonrotoclax in combination therapy for multiple myeloma [16].

Core Viewpoint - The company is actively engaged in the research and development of innovative drugs and biosimilars through its subsidiaries, with several products nearing market readiness [2]. Group 1: Product Development - Bevacizumab has obtained its drug registration certificate in November 2024, and will commence production and sales [2]. - Rituximab and Dexamethasone are expected to complete clinical studies and submit drug registration applications by November 2024 and December 2025, respectively, with their applications already accepted [2]. - Other products, including Adalimumab, Trastuzumab, Ipilimumab, and several monoclonal antibodies and fusion proteins, have received clinical approval and are undergoing related clinical studies, contributing to the company's new profit growth points and product portfolio enhancement [2].

Core Viewpoint - Maiwei Biotech has received approval from the China Securities Regulatory Commission (CSRC) to issue up to 62.66 million overseas listed ordinary shares, aiming for a listing on the Hong Kong Stock Exchange, driven by ongoing losses and urgent funding needs for research and development [1][2]. Group 1: IPO Journey - Maiwei Biotech's journey to an IPO in Hong Kong has faced challenges, including a previous application submitted on January 6, which was interrupted by an investigation into the chairman for alleged insider trading [2]. - The chairman, Liu Datao, was found to have engaged in short-term trading of the company's shares, resulting in a warning and a fine of 600,000 yuan, which raised concerns about the company's internal governance [2]. - After the initial application expired, the company resubmitted its listing application on August 29, and the recent approval indicates that it has completed the necessary preparatory work for the listing [2]. Group 2: Financial Performance - Maiwei Biotech has been in a state of continuous loss since its listing on the STAR Market in 2022, with cumulative losses exceeding 3.6 billion yuan from 2022 to the first half of 2025, while total revenue during the same period was only 457 million yuan [4][5]. - The company reported a significant revenue increase of 301.03% in the third quarter of 2025, with total revenue reaching 566 million yuan, although it still faced a net loss of 598 million yuan, which was a 13.89% reduction year-on-year [4]. - The company has invested heavily in research and development, with cumulative R&D expenses exceeding 2.7 billion yuan from 2022 to the first half of 2025, which has contributed to its financial strain [5]. Group 3: Future Outlook - The company emphasizes the need for sufficient funding through its planned H-share listing to alleviate liquidity risks and support ongoing research and development activities [5]. - The approval for the H-share issuance is contingent upon further approvals from relevant regulatory bodies in Hong Kong, indicating that uncertainties remain regarding the completion of the listing process [3].

Summary of the Conference Call for Maiwei Biotech Company Overview - **Company**: Maiwei Biotech - **Date**: November 4, 2025 Key Points Financial Performance - As of September 30, the company reported cash and cash equivalents of 1.439 billion RMB, an increase of over 200 million RMB compared to the end of last year [5] - Revenue for the first three quarters reached 566 million RMB, a year-on-year increase of 300%, driven by growth in technical service fees and a 70% increase in the sales of Dizu monoclonal antibody [5] - The loss for the third quarter significantly reduced to 49 million RMB, a year-on-year decrease of 200 million RMB, marking the first substantial reduction in losses [5] Business Development (BD) Achievements - The company achieved multiple breakthroughs in BD, including collaborations on Bai Jie 11, small nucleic acids, and long-acting Shengmai injections, resulting in over 800 million RMB in cash inflow [6][7] - Several BD pipelines are in progress, including 94 ADR BTC, CDED, and STE U monoclonal antibodies, with expectations for more results in the future [7] Core Projects and Pipeline Progress - The core pipeline includes 9KT 4 ADC, B713 ADC, and CD17 ADC, with multiple products expected to be approved and initiate patient enrollment in both China and the U.S. [8] - The SE2 monoclonal antibody for COPD has completed enrollment of 80 patients in the EB27 clinical trial, with expectations to complete follow-up by the end of the year [3] - The company is also advancing the CDH17 ADC project, which has received overseas authorization with a total amount exceeding 1 billion USD for liver delivery exploration [3][4] Market Expansion and Product Launches - Dizu monoclonal antibody sales approached 100 million RMB in the first half of the year, ranking first among domestic products [16] - The company has signed agreements with over 10 countries to expand biosimilars into emerging markets, with the first launch in Pakistan in August [16] - A supplemental application for bone metastasis indications is expected to be approved in the first half of next year, which could significantly increase revenue [16] Future Development Plans - The company is focusing on four key platforms: antibody discovery, ADC, TCE, and small nucleic acids, with plans to launch more TCE products into clinical trials next year [8] - The company is also developing treatments for age-related diseases, such as the SE2 monoclonal antibody for COPD, with plans for larger sample size trials [8] Clinical Trials and Regulatory Approvals - The company is actively communicating with the FDA regarding clinical trial designs and endpoints, particularly for the Bai Jie 11 project targeting pathological scars [9][28] - The 2,821 project is expected to focus on single endpoint PFS (Progression-Free Survival) to shorten clinical cycles and sample sizes [18][25] Innovations in Drug Development - The siRNA platform has been authorized to Editas, with ongoing development of dual-target siRNA and exploration of liver and CNS delivery systems [12][33] - The company is also developing a new oral small molecule drug for osteoarthritis, which is currently advancing to phase II clinical trials [14] Market Outlook - The company anticipates significant revenue growth from traditional products like Dizu and Adalimumab, with a complete transition to Maiwei's invoicing by 2026 [22] - The aging population in China is expected to drive demand for ophthalmic preparations, particularly for age-related macular degeneration [38] Conclusion - Maiwei Biotech is positioned for growth with a robust pipeline, significant financial improvements, and strategic collaborations, aiming to expand its market presence and enhance its product offerings in the coming years [39]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company reported a significant increase in revenue and has multiple business development (BD) collaborations that are expected to drive future growth [8] - The company has a strong pipeline with clinical advancements in its CDH17 ADC and TCE platform, showcasing its R&D capabilities [8] - Revenue projections for 2025-2027 are estimated at 9.03 billion, 14.31 billion, and 22.72 billion RMB respectively, with a path to profitability expected by 2027 [8] Financial Performance - For the third quarter of 2025, the company achieved a revenue of 465 million RMB, representing a year-on-year growth of 1717.41% [8] - The total revenue for the first three quarters of 2025 reached 566 million RMB, a year-on-year increase of 301.03% [8] - The company's drug sales revenue for the third quarter was 55.32 million RMB, up 120.85% year-on-year, and for the first three quarters, it was 156 million RMB, up 72.10% year-on-year [8] Business Development Collaborations - The company has secured three BD collaborations, including a partnership with Qilu Pharmaceutical for the Agrestin α product, which includes a 380 million RMB upfront payment [8] - Collaborations with Calico and Kalexo involve significant upfront payments and milestone payments, indicating strong commercial potential [8] Clinical Development - The company’s self-developed CDH17 ADC has received approval for clinical trial applications from both the National Medical Products Administration and the FDA [8] - The TCE platform has established a comprehensive antibody library, enhancing its capabilities for targeted cancer therapies [8] Earnings Forecast - Projected revenues for 2025, 2026, and 2027 are 9.03 billion, 14.31 billion, and 22.72 billion RMB respectively, with corresponding net profits expected to be -648 million, -301 million, and 80 million RMB [7][8] - The company is expected to achieve an EPS of -1.62, -0.75, and 0.20 RMB for the years 2025, 2026, and 2027 respectively [7]